Sonoma Pharmaceuticals (SNOA) Gross Margin (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Gross Margin of 37.94% in Q4 2025, little changed quarter-over-quarter from 37.83% in Q3 2025, and up 231.0% on a YoY basis from 11.46% in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Gross Margin (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Gross Margin history runs 16 years deep, the most recent figure standing at 37.94% for Q4 2025.
- In Q4 2025, Gross Margin rose 231.0% year-over-year to 37.94%; the TTM figure through Dec 2025 stood at 38.16% (up 217.0% YoY), while the FY2025 annual figure was 38.25%, up 99.0% from the prior year.
- Gross Margin was 37.94% for Q4 2025 at Sonoma Pharmaceuticals, roughly flat from 37.83% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 46.53% in Q4 2023 to a low of 8.99% in Q1 2021.
- Historically, Gross Margin has averaged 33.42% across 5 years, with a median of 37.15% in 2025.
- The sharpest annual moves came in 2021 and 2023: Gross Margin plunged 4733 bps in 2021, then surged 2449 bps in 2023.
- A 5-year view of Gross Margin shows it stood at 41.45% in 2021, then tumbled by 32 bps to 28.23% in 2022, then soared by 65 bps to 46.53% in 2023, then retreated by 23 bps to 35.63% in 2024, then rose by 6 bps to 37.94% in 2025.
- The last three Gross Margin figures came in at 37.94% (Q4 2025), 37.83% (Q3 2025), and 36.46% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -293.83% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 61.20% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 65.25% |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | 37.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 37.94% |
| Sep 30, 2025 | 37.83% |
| Jun 30, 2025 | 36.46% |
| Mar 31, 2025 | 40.70% |
| Dec 31, 2024 | 35.63% |
| Sep 30, 2024 | 38.03% |
| Jun 30, 2024 | 38.51% |
| Mar 31, 2024 | 31.72% |
| Dec 31, 2023 | 46.53% |
| Sep 30, 2023 | 36.25% |
| Jun 30, 2023 | 35.13% |
| Mar 31, 2023 | 28.67% |
| Dec 31, 2022 | 28.23% |
| Sep 30, 2022 | 46.11% |
| Jun 30, 2022 | 41.33% |
| Mar 31, 2022 | 4.18% |
| Dec 31, 2021 | 41.45% |
| Sep 30, 2021 | 33.15% |
| Jun 30, 2021 | 39.44% |
| Mar 31, 2021 | -8.99% |